AbbVie Inc. (ABBV)
| Chiusura precedente | 152,49 |
| Aperto | 153,90 |
| Denaro | 154,29 x 900 |
| Lettera | 154,33 x 800 |
| Min-Max giorno | 153,35 - 155,86 |
| Intervallo di 52 settimane | 105,56 - 175,91 |
| Volume | |
| Media Volume | 7.345.593 |
| Capitalizzazione | 275,086B |
| Beta (5 anni mensile) | 0,81 |
| Rapporto PE (ttm) | 22,33 |
| EPS (ttm) | 6,97 |
| Prossima data utili | 28 lug 2022 - 01 ago 2022 |
| Rendimento e dividendo (forward) | 5,64 (4,08%) |
| Data ex dividendo | 14 apr 2022 |
| Stima target 1A | 163,01 |
- GlobeNewswire
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics
Licenses Revolutionary Skin Care Compound TFC-1067VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-106
- FX Empire
Best Dividend Stocks to Buy Now for May 2022
Markets have continued to be volatile for a while as inflation rages. In the past, dividend paying stocks have proven to be good hedges for these kinds of environments.
- FX Empire
Big Money Buying Up AbbVie
AbbVie, Inc. (ABBV) stock has jumped in 2021, trailing the market thus far, but still rising decently at +17.1%. And the pharmaceutical giant could rise even more due to strong growth prospects. But another likely reason is Big Money lifting the stock.
